CIPLA · Pharma & Healthcare · large cap · Nifty 50
What the business sold
What it kept after tax
Profit from operations
Cash the operations produced
Borrowings against the business
Paid out per share · not collected yet
Price index · Start = 100 · Dividends excluded · ₹1,366 today (-0.53%)
As of 13 Sept 2026
Price to book 3.2
Trailing twelve months
Closing prices
| Reported metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 22,473 | 25,447 | 27,145 | 27,712 |
| Operating profit | 4,018 | 5,369 | 6,144 | 4,846 |
| Net profit | — | — | — | 3,879 |
| Operating cash flow | 3,238 | 4,134 | 5,005 | 3,940 |
| Free cash flow | 2,055 | 2,785 | 3,457 | 861 |
| Capital expenditure | -1,183 | -1,349 | -1,548 | -3,079 |
| Tax expense | 1,203 | 1,547 | 1,530 | 1,354 |
| Total debt | 803 | 559 | 438 | 614 |
| Cash and equivalents | 628 | 640 | 589 | 1,018 |
| Shareholders equity | 23,408 | 26,706 | 31,193 | 34,432 |
| Earnings per share (₹) | 34.69 | 51.01 | 65.24 | 48.00 |
Not collected yet for this company: Dividend per share. These come from the filings, not the daily price feed.
| Quarter ended | Revenue | Operating profit | Net profit | EPS (₹) |
|---|---|---|---|---|
| 30 Jun 2026 | 7,077 | 888 | 789 | 9.76 |
| 31 Mar 2026 | 6,464 | 614 | 555 | 6.86 |
| 31 Dec 2025 | 6,963 | 977 | 676 | 8.36 |
| 30 Jun 2025 | 6,837 | 1,525 | 1,298 | 16.06 |
| 31 Mar 2025 | 6,598 | 1,229 | 1,222 | 15.12 |
The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.75. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
A real announcement — a product, a partnership, an appearance — that is unlikely to change the financials.
Classifier confidence: 0.35. This is not the probability that the report is true.
The headline states a business fact and a direction that helps it. This classifies the headline only, not the full article. It is not a recommendation.
Somebody's reading of events rather than an event. Worth the argument; not a filing.
Classifier confidence: 0.80. This is not the probability that the report is true.
No supported direction in the headline — that is not the same as unimportant. This classifies the headline only, not the full article. It is not a recommendation.
Names an event that should show up in revenue, profit, debt, capacity or approvals.
Classifier confidence: 0.35. This is not the probability that the report is true.
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Industry: Drug Manufacturers - Specialty & Generic
Prices, fundamentals and developments last verified 13 Sept 2026. Fundamentals are sourced from public filings feeds; interpretation is shown separately from figures.
Guests see a sample. Members get every company, five-year fundamentals, classified developments, a watchlist and the decision journal.
Sign in with Google